Method for inguinal hernia treatment
SUBSTANCE: in the medial part of the patient's inguinal canal lying on the back, a polymerizable mixture consisting of three solutions A, B and C is introduced by injection through the needle. Solution A is a solution of a copolymer of acrylamide and hydroxysuccinimide ester of acrylic acid. Solution B is a solution of 1,4-butanediamine and succinic acid. Solution C is a solution of sodium hydrogencarbonate. The molar ratio of acrylamide and hydroxysuccinimide ester of acrylic acid in the copolymer is selected in the range of 9:1 to 7:3, the molar ratio of 1,4-butanediamine to succinic acid in solution B is selected in the range of 4:1 to 1:1. The concentration of solution A was selected from the mass concentration of the copolymer in solution A in the range 21.8-26.3 g/l. The concentration of solution B is: for 1,4-butanediamine - about 22.0 g/l, for succinic acid - in the range of 7.4-29.5 g/l. The concentration of solution C is in the range of 0.6-1.1 mol/l. The ratio of the quantity of solutions A and B is chosen so that the molar ratio of hydroxysuccinimide ester of acrylic acid in the copolymer and 1,4-butanediamine does not exceed 2:1. The ratio of the quantity of solutions B and C is selected from the condition that the molar ratio of sodium hydrogencarbonate and succinic acid is not less than 2:1. The mixture is prepared by successively mixing solutions A and B and then solution C. Then, the prepared mixture is injected until the inguinal canal is filled and the patient is left in the indicated position until the polymerization of the mixture introduced into the inguinal channel is completed.
EFFECT: invention allows minimally invasive elimination of hernial protrusion, reliable closure of hernial gates, and prevention of recurrent inguinal hernia.
7 cl, 9 dwg
SUBSTANCE: phenazepamum 1.0 mg is prescribed per os to patient on the eve of planned operation; then, in pre-narcosis room after catheterisation of peripheral vein suprastinum in dose 0.3 mg/kg of patient's body weight and atropine in dose 0.01 mg/kg of patient's body weight are introduced intramuscularly 30 minutes before operation. After that, solution of dexmedetomidine with concentration 4.0 mkg/ml in dose 1.0 mcg/kg of patient's body weight is introduced by intravenous infusion by syringe-batcher for 10 min.
EFFECT: method ensures optimal level of sedation and stability of haemodynamics indexes at the background of reduction of patient's psycho emotional stress and preservation of their contact with medical staff.
SUBSTANCE: described is a method of bone tissue substitution, in which as a bone-substituting material applied is a biodegradable material of the following composition, wt %: biological hydroxyapatite - 50-52, magnesium phosphate - 30-32, calcium hydrophosphate - 8-10, calcium hydroxide - 4.8-5.3, sodium alginate - the remaining part. As a binding agent applied is casein in the form of an ammonia solution with the ratio of powder mass of the biodegradable material to the ammonia casein solution of 1:1-1.5.
EFFECT: reduction of terms and improvement of surgical operation results.
4 dwg, 2 tbl, 2 ex
SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for the enhancement of hemocirculation in a suture belt of the interintestinal anastomosis in experiment. For this purpose 0.25% solution of trimecaine is introduced in a dose of 400-88 ml per day into the mesentery of the intestine in the zone of the anastomosis under peritonitis conditions in dogs after the small intestine resection. 500 IU of heparin and a daily dose of an antibiotic are additionally added into the trimecaine solution.
EFFECT: method provides the enhancement of hemocirculation in suture belts of the interintestinal anastomosis due to the increase of intramural pressure.
SUBSTANCE: invention relates to chemistry and presents a conjugation product, comprising polysaccharides T1 and T2, where the monosaccharides which form the polysaccharides T1 and T2 are bonded to each other by alpha-1,4-glycosidic links. At least one of the polysaccharides T1 and/or T2 comprises at least one amino group. T1 and T2 are bonded to each other covalently by a linker. T1 and/or T2 carry m groups -(L-A), wherein A is glucosaminoglycan or a derivative of glucosaminoglycan, glucosaminoglycan or a derivative of glucosaminoglycan with fluorescence labels, L is a second linker, by which T1 and/or T2 are covalently bonded to A, and m is at least 1.
EFFECT: invention also relates to a pharmaceutical composition, comprising a bonded product; use of the product in medicine and cosmetology and to the method of preparation of the bonded product.
22 cl, 5 ex
SUBSTANCE: interlaminectomy preserving a yellow ligament is performed. A sequestrum is visualised and removed. An EOC-controlled laser light guide is inserted into the intervertebral disk through its injured portion. That is followed by a laser vaporisation of a nucleus pulposus with a 3- or 4-pulse train, power 20 Wt, length 1 s, interval 2 s in a total dose of 940-1,000 J. An operative aid area is filled with Oxiplex® gel from epidural-periradicular-subligamentous direction.
EFFECT: method provides preventing postdiskectomy syndrome by preventing epidural fibrosis by preserving the yellow ligaments in a combination with using Oxiplex gel, and recurrent disk hernia by laser disk repair.
2 cl, 4 dwg, 1 ex
SUBSTANCE: solution containing fibrin monomer in the concentration of 11 mg/ml and urea in the concentration of 150 mg/ml is introduced intravenously into male rabbits experimentally one hour before the surgical intervention. A dose of fibrin monomer is 0.25 mg/kg.
EFFECT: method possess the high effectiveness as both reduces the bleeding volume, but causes the severe haemodynamic disturbances and allergic reactions.
SUBSTANCE: treating mastoid diseases complicated with thrombophlebitis involves removing a pathologically changed bone, opening all mastoid process cells, exposing a sigmoid sinus and puncturing it with removing a thrombus. That is followed by plugging a sinus lumen with High-structure sodium alginate hydrogel matrix with pre-added dioxidine 0.03 g. The matrix surface is coated with Hydrogel Coletex AKL tissue. The antretomastoid cavity walls are covered with the same material, whereas a latex tampon pre-coated with Hydrogel Coletex-ADL tissue is used for plugging.
EFFECT: method provides the early generation of granulation tissue, the protective and haemostatic effect in the wound, reduces the length of treatment, prevents early and late complications and thereby improving the patient's quality of life.
3 dwg, 2 ex
SUBSTANCE: 0.5% dihydroquercetin is instilled into the rectum of a patient with temporary colostomy until he/she starts feeling intestinal inflation. The procedure is performed twice a day, daily up until the restorative surgery.
EFFECT: method reduces a rate and a degree of colitis manifestations by the local antioxidant, anti-inflammatory effect, unfolding the excluded colon.
SUBSTANCE: ozone-oxygen mixture is administered from both sides of a retroperitoneal space into paranephric fat in an amount of up to 500 mg included from each side. The ozone concentration makes 10 mg/l and less. The therapeutic course makes 5-10 sessions every 1-3 days.
EFFECT: effective treatment of the given pathology by supplying the ozone-oxygen mixture directly to an arterial trunk that causes its targeted action.
SUBSTANCE: frontal sinus is approached in a typical location and sanitated. After the sanitation procedure, a bone defect is covered with high-structure hydrogel matrix of sodium alginate, wherein dioxidin 0.03g and ε-aminocapronic acid 0.15g are pre-administered. The sinus is obliterated with MK-9M osteoplastic composition. The approach point is covered with the same matrix, on the top of which the wound is closed completely and coated with Coletex-ADL hydrogel tissue.
EFFECT: method provides preventing early and late suppurative complications, promotes preventing intracranial complications, reduces the recovery time by the protective antiseptic, homeostatic, antitoxic properties of the used matrix, which prevents the composition prolapse into the intracranial cavity as a brace.
4 dwg, 2 ex
SUBSTANCE: water-soluble iodine-containing contrast substance is introduced to a patient intravenously, computer tomography is carried out, after which the point measurement of densitometric indices is carried out before and after obstruction in each contrasted coronary artery (CA). If the density of the contrasted CA lumen before and after obstruction at least in one of them differs by more than 80 HU, the degree of injury is considered to be haemodynamically significant, and surgical treatment is indicated to the patient.
EFFECT: method makes it possible to estimate the functional significance of CA stenosis in a single step and with high accuracy due to the integrated CT estimation of the coronary blood flow in the entire CA.
SUBSTANCE: invention refers to medicine, particularly to vascular and endovascular surgery, and can be used to assess the state of an isolated aneurismal sac after a stent graft implantation by measuring a pressure inside the sac, as well as for introducing drugs into the blood vessel aneurism as it may be required. The device for pressure measurement in the isolated cavity of the aneurismal sac and for drug introduction into the blood vessel aneurism is configured as a hollow tube. The tube has side holes and is configured to reshape when inserted into the aneurism, to fill its inner space circumferentially, to attach by a two-piece hollow tube to a pressure sensor to measure a pressure between the vascular wall and the wall of the stent graft implanted into the blood vessel, as well as to introduce drugs by means of the above two-piece hollow tube. The tube is made of a viscoelastic absorbable material and spiral-shaped.
EFFECT: invention enables solving a set of challenges: saving the manufacturing expenses, simplifying the course of the surgical intervention, measuring the pressure, introducing the drugs, improving the immediate and remote results by ensured thrombosing of the aneurismal sac.
5 cl, 3 dwg
SUBSTANCE: group of inventions refers to medicine, particularly to treating bronchopulmonary dysplasia. A method involves administering an effective amount of citrulline into the patient. What is also presented is a pharmaceutical composition applicable for intravenous administration, containing a pharmaceutically acceptable carrier and an amount of citrulline effective for increasing blood plasma citrulline. The level is measured by comparing plasma citrulline in the patient under treatment to that in the patient having no bronchopulmonary dysplasia. The given composition is presented for producing a preparation for injections.
EFFECT: inventions provide the effective treatment of bronchopulmonary dysplasia by the polycomponent effect of citrulline on the disease process.
11 cl, 8 dwg, 2 tbl, 4 ex
SUBSTANCE: group of inventions refers to medicine. A drug delivery control unit comprises a user's interface configured to receive input data. The input data comprises patient's data and/or drug data and/or vascular access device data. A sensor is configured to measure a liquid pressure rate in a liquid delivery canal, which is used to deliver the drug to a patient's infusion site by means of the vascular access device. A processor is configured to assess a model state of the infusion site on the basis of the pressure rate in the liquid delivery canal and the input data. An output device notifies, supplies an urgent signal and/or a graphic/digital indication if the assessed model state of the infusion site and the liquid pressure rate in the liquid delivery canal to the infusion site testifies to infiltration. There are disclosed a method for controlling the drug delivery and a computer-readable carrier containing commands for implementing the method.
EFFECT: inventions enable detecting the infiltration condition and notify about the same.
16 cl, 6 dwg, 1 tbl
SUBSTANCE: invention refers to medicine, namely to urology. A stent representing a threaded metal spiral is installed into the prostatic urethra with the use of a guide and the Foley catheter. The hollow rigid metal guide is curved along the urethral flexure, provided with a handle on the outer end and an inner thread on the inner end. The spiral stent is attached to the guide, and the Foley catheter is inserted therein. The device is installed into the prostatic urethra. The Foley catheter balloon is emptied. The catheter is removed. The guide is detached from the spiral and removed from the urethra.
EFFECT: method simplifies the delivery and provides the accurate installation of the urethral stent into the prostatic urethra by avoiding the necessity of using endoscopic equipment with a simple procedure for the guide and catheter removal from the urethra.
SUBSTANCE: endovascular embolisation of the uterine arteries are approached through a radial artery. Khair diagnostic catheter is inserted at the bifurcation of the abdominal aorta. Khair catheter tip is rotated to the right to provides sequential catheterisation of the right internal iliac and uterine arteries. That is followed by embolisation of the right uterine artery. Thereafter, Khair diagnostic catheter is pulled back up to the bifurcation of the abdominal aorta, and its tip is rotated to the left. That is followed by sequential catheterisation of the left internal iliac and uterine arteries. That is followed by embolisation of the left uterine artery. Khair diagnostic catheter and introducer are removed, and haemostasis is performed.
EFFECT: method enables reducing the length of the procedure, a radiation-absorbed dose and a rate of the following complications; it promotes early mobilisation of the patient after the procedure.
SUBSTANCE: invention relates to medical equipment, namely, to means of endovascular device positioning. An adaptor contains an element, which has two ends and an internal lumen, made in such a way that when one end is connected to a catheter, and the other end is connected to a syringe, liquid from the syringe flows through the lumen into the catheter. A metal ring is located along the internal lumen of the element fully inside the said element in such a way that the metal ring is brought into electric contact with the liquid, when it flows from the syringe into the catheter, with the metal ring being connected to the external side of the element by means of insulated electric connection.
EFFECT: application of the invention makes it possible to increase the reliability of connection of the catheter and the syringe.
18 cl, 15 dwg
SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.
EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.
15 cl, 20 tbl, 21 dwg, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for treatment of cerebral glioma. For this purpose combination of cannabinoids-tetrahydrocannabinol (THC) and cannabidiol (CBD) and non-cannabinoid chemotherapeutic agent is claimed. THC and CBD ratio constitutes from 5:1 to 1:5.
EFFECT: combination of anti-tumour medications provides efficient reduction of brain tumour volume due to selective death of transformed cells.
14 cl, 2 tbl, 8 dwg
SUBSTANCE: group of inventions refers to medical equipment. A device for the continuous analysis of a target substance in a body fluid sample comprises a sensitive unit with a subcutaneous sensor for obtaining the target substance information, a power source for power supply to the sensor and a data storage unit for the sensor data storage. The device data storage unit for the continuous analysis is detachably connected to the sensitive unit and comprises a storage container. The control unit of the device for the continuous analysis is configured to control the relevant data storage from the part of data storage in the storage container, when the storage unit is attached to the sensitive unit, and to control the data transmission from the storage container, when the storage container remote from the sensitive unit is attached to an external device. The system controlling the target substance in the body fluid sample comprises the device for continuous control and the external device which is provided with the storage containers for the relevant data storage as obtained from the sensor or from the storage container. The data storage unit and the external device are detachably connected.
EFFECT: using the group of inventions enables providing the more accurate transmission of the body fluid ingredients data to the external device.
15 cl, 11 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, namely to a formulation of a cough medical composition. The formulation of the cough medical composition contains an active substance presented by thermopsis herb powder or a dry extract of thermopsis and sodium hydrocarbonate, as well as an excipient, a granulating agent and a lubricant taken in certain relations (versions).
EFFECT: composition of the cough medical composition possesses improved pharmaceutical (appearance, taste) and technological characteristics (hardness, disintegration).
11 cl, 7 ex